Michael Nordtvedt

Wilson Sonsini Goodrich & Rosati

+ Follow Contact

Latest Posts › Life Sciences

Share:

2024 Technology and Life Sciences PIPE and RDO Report

Wilson Sonsini's 2024 Technology and Life Sciences PIPE and RDO Report provides an analysis of 205 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences...more

3/25/2025 / Capital Markets , Investment , Investors , Life Sciences , Publicly-Traded Companies , Securities Regulation , Technology Sector

2024 Technology and Life Sciences IPO Report

Wilson Sonsini's 2024 Technology and Life Sciences IPO Report provides in-depth analysis on 33 initial public offerings (IPOs) completed by U.S.-based technology and life sciences companies in 2024 with deal values exceeding...more

2/28/2025 / Capital Markets , Financial Services Industry , Initial Public Offering (IPO) , Investment , Life Sciences , Publicly-Traded Companies , Securities , Securities and Exchange Commission (SEC) , Securities Regulation , Technology Sector

2023 Technology and Life Sciences IPO Report

Market volatility, high interest rates, and ongoing geopolitical conflict continue to influence low levels of IPO activity in the U.S. capital markets. The trend is observed across all sectors, resulting in IPO levels similar...more

3/29/2024 / Board of Directors , Corporate Governance , Emerging Growth Companies , Emerging Technology Companies , Initial Public Offering (IPO) , Life Sciences , Non-GAAP Financial Measures , Technology Sector

2023 Technology and Life Sciences PIPE and RDO Report

The 2023 Technology and Life Sciences PIPE and RDO Report presents analysis related to 177 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by U.S.-based technology and life sciences...more

2/23/2024 / Capital Markets , Fiduciary Duty , Initial Public Offering (IPO) , Investors , Life Sciences , Private Investment in Public Equity (PIPEs) , Rule 10b-5 , Securities , Shareholders , Technology Sector

2023 Mid-Year Technology and Life Sciences PIPE and RDO Report

Wilson Sonsini Goodrich & Rosati’s 2023 Mid-Year Technology and Life Sciences PIPE and RDO Report presents analysis related to 87 private investments in public equity (PIPEs) and registered direct offerings (RDOs) by...more

9/13/2023 / Business Development , Investment , Life Sciences , Private Equity , Private Equity Funds , Private Investment in Public Equity (PIPEs) , Publicly-Traded Companies , Special Purpose Acquisition Companies (SPACs) , Technology , Technology Sector

5 Results

View per page

Page: of 1